The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models

Download Download as PDF (Size:3167KB)  HTML    PP. 966-1005  
DOI: 10.4236/ijcm.2014.516129    3,000 Downloads   3,652 Views   Citations
Author(s)    Leave a comment


The notion that animals could be used as predictive models in science has been influenced by relatively recent developments in the fields of complexity science, evolutionary and developmental biology, genetics, and evolutionary biology in general. Combined with empirical evidence, which has led scientists in drug development to acknowledge that a new, nonanimal model is needed, a theory—not a hypothesis—has been formed to explain why animals function well as models for humans at lower levels of organization but are unable to predict outcomes at higher levels of organization. Trans-Species Modeling Theory (TSMT) places the empirical evidence in the context of a scientific theory and thus, from a scientific perspective, the issue of where animals can and cannot be used in science has arguably been settled. Yet, some in various areas of science or science-related fields continue to demand that more evidence be offered before the use of animal models in medical research and testing be abandoned on scientific grounds. In this article, I examine TSMT, the empirical evidence surrounding the use of animal models, and the opinions of experts. I contrast these facts with the opinions and positions of those that have a direct or indirect vested interest—financial or otherwise—in animal models. I then discuss the ethical implications regarding research constructed to find cures and treatments for humans.

Cite this paper

Greek, R. (2014) The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models. International Journal of Clinical Medicine, 5, 966-1005. doi: 10.4236/ijcm.2014.516129.


[1] Greek, R. (2008) Letter. Dogs, Genes and Drugs. American Scientist, 96, 4.
[2] Shanks, N., Greek, R. and Greek, J. (2009) Are Animal Models Predictive for Humans? Philosophy, Ethics, and Humanities in Medicine, 4, 2.
[3] Greek, R. and Greek, J. (2010) Is the Use of Sentient Animals in Basic Research Justifiable? Philosophy, Ethics, and Humanities in Medicine, 5, 14.
[4] Greek, R., Hansen, L.A. and Menache, A. (2011) An Analysis of the Bateson Review of Research Using Nonhuman Primates. Medicolegal and Bioethics, 1, 3-22.
[5] Greek, R. and Shanks, N. (2011) Complex Systems, Evolution, and Animal Models. Studies in History and Philosophy of Biological and Biomedical Sciences, 42, 542-544.
[6] Greek, R., Shanks, N. and Rice, M.J. (2011) The History and Implications of Testing Thalidomide on Animals. The Journal of Philosophy, Science & Law, 11.
[7] Greek, R. (2012) Animal Models and the Development of an HIV Vaccine. Journal of AIDS & Clinical Research, S8, 1.
[8] Greek, R. (2012) Book Review. Zoobiquity: What Animals Can Teach Us about Health and the Science of Healing. Animals, 2, 559-563.
[9] Greek, R. and Hansen, L.A. (2012) The Development of Deep Brain Stimulation for Movement Disorders. Journal of Clinical Research & Bioethics, 3, 338-345.
[10] Greek, R., Menache, A. and Rice, M.J. (2012) Animal Models in an Age of Personalized Medicine. Personalized Medicine, 9, 47-64.
[11] Greek, R., Pippus, A. and Hansen, L.A. (2012) The Nuremberg Code Subverts Human Health and Safety by Requiring Animal Modeling. BMC Medical Ethics, 13, 16.
[12] Greek, R. and Rice, M.J. (2012) Animal Models and Conserved Processes. Theoretical Biology and Medical Modelling, 9, 40.
[13] Greek, R. (2013) Animal Models of Cancer in Light of Evolutionary Biology and Complexity Science. The Research and Biology of Cancer, Concept Press, Hong Kong.
[14] Greek, R. (2013) Animal Models in Drug Development. In: Gowder, S., Ed., New Insights into Toxicity and Drug Testing, InTech, Manhattan, 124-152.
[15] Greek, R. and Hansen, L. (2013) The Strengths and Limits of Animal Models as Illustrated by the Discovery and Development of Antibacterials. Biological Systems: Open Access, 2, 109.
[16] Greek, R. and Hansen, L.A. (2013) Questions Regarding the Predictive Value of One Evolved Complex Adaptive System for a Second: Exemplified by the SOD1 Mouse. Progress in Biophysics and Molecular Biology, 113, 231-253.
[17] Greek, R. and Menache, A. (2013) Systematic Reviews of Animal Models: Methodology versus Epistemology. International Journal of Medical Sciences, 10, 206-221.
[18] Jones, R.C. and Greek, R. (2013) A Review of the Institute of Medicine’s Analysis of Using Chimpanzees in Biomedical Research. Science and Engineering Ethics, 20, 481-504.
[19] Greek, R. and Shanks, N. (2009) FAQs about the Use of Animals in Science: A Handbook for the Scientifically Perplexed. University Press of America, Lanham.
[20] Shanks, N. and Greek, R. (2009) Animal Models in Light of Evolution. Brown Walker, Boca Raton.
[21] Schiller, J. (1967) Claude Bernard and Vivisection. Journal of the History of Medicine and Allied Sciences, 22, 246-260.
[22] Sechzer, J.A. (1983) The Ethical Dilemma of Some Classical Animal Experiments. Annals of the New York Academy of Sciences, 406, 5-12.
[23] Anderson, B.O. and Harken, A.H. (1992) Carl John Wiggers’ Visionary Views on Vivisection. Annals of Surgery, 216, 80-86.
[24] Rupke, N. (1987) Vivisection in Historical Perspective. Routledge, London.
[25] Mayer, J. (2008) The Expression of the Emotions in Man and Laboratory Animals. Victorian Studies, 50, 399-417.
[26] Bernard, C. (1957) An Introduction to the Study of Experimental Medicine. 1865. Dover, New York.
[27] Darwin, C. (1936) The Descent of Man and Selection in Relation to Sex. Modern Library, New York.
[28] LaFollette, H. and Shanks, N. (1994) Animal Experimentation: The Legacy of Claude Bernard. International Studies in the Philosophy of Science, 8, 195-210.
[29] Milner, R. (2009) Darwin’s Universe: Evolution from A to Z. University of California Press, Berkeley.
[30] Osler, W. (1907) The Historical Development and Relative Value of Laboratory and Clinical Methods in Diagnosis. The Evolution of the Idea of Experiment in Medicine. Transactions of the Congress of American Physicians and Surgeons, 7, 1-8.
[31] Greek, R. and Hicks, J. (2006) Debate on Animal Experimentation at the University of California-Irvine.
[32] Bailey, J., Thew, M. and Balls, M. (2013) An Analysis of the Use of Dogs in Predicting Human Toxicology and Drug Safety. ATLA, 41, 335-350.
[33] Ahn, A.C., Tewari, M., Poon, C.S. and Phillips, R.S. (2006) The Limits of Reductionism in Medicine: Could Systems Biology Offer an Alternative? PLoS Medicine, 3, e208.
[34] Csete, M.E. and Doyle, J.C. (2002) Reverse Engineering of Biological Complexity. Science, 295, 1664-1669.
[35] Goodwin, B. (2001) How the Leopard Changed Its Spots : The Evolution of Complexity. Princeton University Press, Princeton.
[36] Jura, J., Wegrzyn, P. and Koj, A. (2006) Regulatory Mechanisms of Gene Expression: Complexity with Elements of Deterministic Chaos. Acta Biochimica Polonica, 53, 1-10.
[37] Kauffman, S.A. (1993) The Origins of Order: Self-Organization and Selection in Evolution. Oxford University Press, Oxford.
[38] Kitano, H. (2002) Computational Systems Biology. Nature, 420, 206-210
[39] Kitano, H. (2002) Systems Biology: A Brief Overview. Science, 295, 1662-1664.
[40] Lewin, R. (1999) Complexity: Life at the Edge of Chaos. The University of Chicago Press, Chicago.
[41] Morowitz, H.J. (2002) The Emergence of Everything: How the World Became Complex. Oxford University Press, Oxford.
[42] Ottino, J.M. (2004) Engineering Complex Systems. Nature, 427, 399.
[43] Van Regenmortel, M. (2004) Reductionism and Complexity in Molecular Biology. Scientists Now Have the Tools to Unravel Biological Complexity and Overcome the Limitations of Reductionism. EMBO Reports, 5, 1016-1020.
[44] van Regenmortel, M. (2004) Biological Complexity Emerges from the Ashes of Genetic Reductionism. Journal of Molecular Recognition, 17, 145-148.
[45] Van Regenmortel, M.H. and Hull, D.L. (2002) Promises and Limits of Reductionism in the Biomedical Sciences (Catalysts for Fine Chemical Synthesis). Wiley, West Sussex.
[46] Vicsek, T. (2002) The Bigger Picture. Nature, 418, 131.
[47] Gell-Mann, M. (1994) The Quark and the Jaguar: Adventures in the Simple and Complex. Little, Brown and Company, Boston.
[48] Spear, B.B., Heath-Chiozzi, M. and Huff, J. (2001) Clinical Application of Pharmacogenetics. Trends in Molecular Medicine, 7, 201-204.
[49] Koren, G., Cairns, J., Chitayat, D., Gaedigk, A. and Leeder, S.J. (2006) Pharmacogenetics of Morphine Poisoning in a Breastfed Neonate of a Codeine-Prescribed Mother. Lancet, 368, 704.
[50] Bhathena, A. and Spear, B.B. (2008) Pharmacogenetics: Improving Drug and Dose Selection. Current Opinion in Pharmacology, 8, 639-646.
[51] Hughes, A.R., Spreen, W.R., Mosteller, M., Warren, L.L., Lai, E.H., Brothers, C.H., Cox, C., Nelsen, A.J., Hughes, S., Thorborn, D.E., Stancil, B., Hetherington, S.V., Burns, D.K. and Roses, A.D. (2008) Pharmacogenetics of Hypersensitivity to Abacavir: From PGx Hypothesis to Confirmation to Clinical Utility. Pharmacogenomics Journal, 8, 365-374.
[52] Blair, E. (2009) Predictive Tests and Personalised Medicine. Drug Discovery World, 27-31.
[53] Bates, S. (2010) Progress towards Personalized Medicine. Drug Discovery Today, 15, 115-120.
[54] Dolgin, E. (2010) Big Pharma Moves from “Blockbusters” to “Niche Busters”. Nature Medicine, 16, 837.
[55] Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A., O’Dwyer, P.J., Lee, R.J., Grippo, J.F., Nolop, K. and Chapman, P.B. (2010) Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine, 363, 809-819.
[56] Froehlich, T.E., Epstein, J.N., Nick, T.G., Melguizo Castro, M.S., Stein, M.A., Brinkman, W.B., Graham, A.J., Langberg, J.M. and Kahn, R.S. (2011) Pharmacogenetic Predictors of Methylphenidate Dose-Response in Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 50, 1129-1139.
[57] Hudson, K.L. (2011) Genomics, Health Care, and Society. New England Journal of Medicine, 365, 1033-1041.
[58] Serrano, D., Lazzeroni, M., Zambon, C.F., Macis, D., Maisonneuve, P., Johansson, H., Guerrieri-Gonzaga, A., Plebani, M., Basso, D., Gjerde, J., Mellgren, G., Rotmensz, N., Decensi, A. and Bonanni, B. (2011) Efficacy of Tamoxifen Based on Cytochrome P450 2D6, CYP2C19 and SULT1A1 Genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics Journal, 11, 100-107.
[59] Tan, I.B., Ivanova, T., Lim, K.H., Ong, C.W., Deng, N., Lee, J., Tan, S.H., Wu, J., Lee, M.H., Ooi, C.H., Rha, S.Y., Wong, W.K., Boussioutas, A., Yeoh, K.G., So, J., Yong, W.P., Tsuburaya, A., Grabsch, H., Toh, H.C., Rozen, S., Cheong, J.H., Noh, S.H., Wan, W.K., Ajani, J.A., Lee, J.Ä., Tellez, M.S. and Tan, P. (2011) Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology, 141, 476-485.
[60] Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. and Sadee, W. (2011) Intronic Polymorphism in CYP3A4 Affects Hepatic Expression and Response to Statin Drugs. Pharmacogenomics Journal, 11, 274-286.
[61] Belmaker, R., Bersudsky, Y. and Agam, G. (2012) Individual Differences and Evidence-Based Psychopharmacology. BMC Medicine, 10, 110.
[62] Powell, A.A., Talasaz, A.H., Zhang, H., Coram, M.A., Reddy, A., Deng, G., Telli, M.L., Advani, R.H., Carlson, R.W., Mollick, J.A., Sheth, S., Kurian, A.W., Ford, J.M., Stockdale, F.E., Quake, S.R., Pease, R.F., Mindrinos, M.N., Bhanot, G., Dairkee, S.H., Davis, R.W. and Jeffrey, S.S. (2012) Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLoS ONE, 7, e33788.
[63] Aldous, P. (2013) Your Genomic Future: Personalised Medicine Is Here. New Scientist.
[64] Meyer, U.A. (1990) Genetic Polymorphisms of Drug Metabolism. Fundamental & Clinical Pharmacology, 4, 595-615.
[65] Kalow, W. (1991) Interethnic Variation of Drug Metabolism. Trends in Pharmacological Sciences, 12, 102-107.
[66] Gonzalez, F.J. and Idle, J.R. (1994) Pharmacogenetic Phenotyping and Genotyping. Present Status and Future Potential. Clinical Pharmacokinetics, 26, 59-70.
[67] Nebert, D. (1997) Pharmacogenetics: 65 Candles on the Cake. Pharmacogenetics, 7, 435-440.
[68] Nebert, D.W., Ingelman-Sundberg, M. and Daly, A.K. (1999) Genetic Epidemiology of Environmental Toxicity and Cancer Susceptibility: Human Allelic Polymorphisms in Drug-Metabolizing Enzyme Genes, Their Functional Importance, and Nomenclature Issues. Drug Metabolism Reviews, 31, 467-487.
[69] Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O’Callaghan, C.J., Tu, D., Tebbutt, N.C., Simes, R.J., Chalchal, H., Shapiro, J.D., Robitaille, S., Price, T.J., Shepherd, L., Au, H.J., Langer, C., Moore, M.J. and Zalcberg, J.R. (2008) K-Ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359, 1757-1765.
[70] Pirmohamed, M. (2011) Pharmacogenetics: Past, Present and Future. Drug Discovery Today, 16, 852-861.
[71] Macdonald, J.S. (2002) Vive la Difference: Sex and Fluorouracil Toxicity. Journal of Clinical Oncology, 20, 1439-1441.
[72] Sloan, J.A., Goldberg, R.M., Sargent, D.J., Vargas-Chanes, D., Nair, S., Cha, S.S., Novotny, P.J., Poon, M.A., O’Connell, M.J. and Loprinzi, C.L. (2002) Women Experience Greater Toxicity with Fluorouracil-Based Chemotherapy for Colorectal Cancer. Journal of Clinical Oncology, 20, 1491-1498.
[73] Holden, C. (2005) Sex and the Suffering Brain. Science, 308, 1574.
[74] Kaiser, J. (2005) Gender in the Pharmacy: Does It Matter? Science, 308, 1572.
[75] Simon, V. (2005) Wanted: Women in Clinical Trials. Science, 308, 1517.
[76] Couzin, J. (2007) Cancer Research. Probing the Roots of Race and Cancer. Science, 315, 592-594.
[77] Willyard, C. (2009) HIV Gender Clues Emerge. Nature Medicine, 15, 830.
[78] Klein, S. and Huber, S. (2010) Sex Differences in Susceptibility to Viral Infection. In: Klein, S. and Roberts, C., Eds., Sex Hormones and Immunity to Infection, Springer-Verlag, Berlin, 93-122.
[79] Wald, C. and Wu, C. (2010) Of Mice and Women: The Bias in Animal Models. Science, 327, 1571-1572.
[80] Canto, J.G., Rogers, W.J., Goldberg, R.J., Peterson, E.D., Wenger, N.K., Vaccarino, V., Kiefe, C.I., Frederick, P.D., Sopko, G. and Zheng, Z.-J. (2012) Association of Age and Sex with Myocardial Infarction Symptom Presentation and In-Hospital Mortality. JAMA: The Journal of the American Medical Association, 307, 813-822.
[81] Favoni, R.E. and Alama, A. (2013) Preclinical Strategies Targeted at Non-Small-Cell Lung Cancer Signalling Pathways with Striking Translational Fallout. Drug Discovery Today, 18, 11-24.
[82] Lyons, M.R., Peterson, L.R., McGill, J.B., Herrero, P., Coggan, A.R., Saeed, I.M., Recklein, C., Schechtman, K.B. and Gropler, R.J. (2013) Impact of Sex on the Heart’s Metabolic and Functional Responses to Diabetic Therapies. American Journal of Physiology—Heart and Circulatory Physiology, 305, H1584-H1591.
[83] Gregor, Z. and Joffe, L. (1978) Senile Macular Changes in the Black African. British Journal of Ophthalmology, 62, 547-550.
[84] Cheung, D.S., Warman, M.L. and Mulliken, J.B. (1997) Hemangioma in Twins. Annals of Plastic Surgery, 38, 269-274.
[85] Haiman, C.A., Stram, D.O., Wilkens, L.R., Pike, M.C., Kolonel, L.N., Henderson, B.E. and Le Marchand, L. (2006) Ethnic and Racial Differences in the Smoking-Related Risk of Lung Cancer. New England Journal of Medicine, 354, 333-342.
[86] Couzin, J. (2007) Human Genetics. In Asians and Whites, Gene Expression Varies by Race. Science, 315, 173-174.
[87] Nature (2007) Research Highlights. Spot the Difference. Nature, 445, 129.
[88] Spielman, R.S., Bastone, L.A., Burdick, J.T., Morley, M., Ewens, W.J. and Cheung, V.G. (2007) Common Genetic Variants Account for Differences in Gene Expression among Ethnic Groups. Nature Genetics, 39, 226-231.
[89] Stamer, U.M. and Stuber, F. (2007) The Pharmacogenetics of Analgesia. Expert Opinion on Pharmacotherapy, 8, 2235-2245.
[90] Kopp, J.B., Nelson, G.W., Sampath, K., Johnson, R.C., Genovese, G., An, P., Friedman, D., Briggs, W., Dart, R., Korbet, S., Mokrzycki, M.H., Kimmel, P.L., Limou, S., Ahuja, T.S., Berns, J.S., Fryc, J., Simon, E.E., Smith, M.C., Trachtman, H., Michel, D.M., Schelling, J.R., Vlahov, D., Pollak, M. and Winkler, C.A. (2011) APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy. Journal of the American Society of Nephrology, 22, 2129-2137.
[91] Wilke, R.A. and Dolan, M.E. (2011) Genetics and Variable Drug Response. JAMA: The Journal of the American Medical Association, 306, 306-307.
[92] Sarkar, M., Bacchetti, P., French, A.L., Tien, P., Glesby, M.J., Nowicki, M., Plankey, M., Gange, S., Sharp, G., Minkoff, H., Peters, M.G. and Women’s Interagency, H.I.V.S. (2012) Lower Liver-Related Death in African-American Women with Human Immunodeficiency Virus/Hepatitis C Virus Coinfection, Compared to Caucasian and Hispanic Women. Hepatology, 56, 1699-1705.
[93] Xu, H., Cheng, C., Devidas, M., Pei, D., Fan, Y., Yang, W., Neale, G., Scheet, P., Burchard, E.G., Torgerson, D.G., Eng, C., Dean, M., Antillon, F., Winick, N.J., Martin, P.L., Willman, C.L., Camitta, B.M., Reaman, G.H., Carroll, W.L., Loh, M., Evans, W.E., Pui, C.-H., Hunger, S.P., Relling, M.V. and Yang, J.J. (2012) ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology.
[94] Dewland, T.A., Olgin, J.E., Vittinghoff, E. and Marcus, G.M. (2013) Incident Atrial Fibrillation among Asians, Hispanics, Blacks, and Whites. Circulation.
[95] Pinto, J.M., Schumm, L.P., Wroblewski, K.E., Kern, D.W. and McClintock, M.K. (2013) Racial Disparities in Olfactory Loss among Older Adults in the United States. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences.
[96] Herndon, C.N. and Jennings, R.G. (1951) A Twin-Family Study of Susceptibility to Poliomyelitis. American Journal of Human Genetics, 3, 17-46.
[97] Alexanderson, B. and Borga, O. (1972) Interindividual Differences in Plasma Protein Binding of Nortriptyline in Man—A Twin Study. European Journal of Clinical Pharmacology, 4, 196-200.
[98] Lin, T.M., Chen, C.J., Wu, M.M., Yang, C.S., Chen, J.S., Lin, C.C., Kwang, T.Y., Hsu, S.T., Lin, S.Y. and Hsu, L.C. (1989) Hepatitis B Virus Markers in Chinese Twins. Anticancer Research, 9, 737-741.
[99] Fraga, M.F., Ballestar, E., Paz, M.F., Ropero, S., Setien, F., Ballestar, M.L., Heine-Suner, D., Cigudosa, J.C., Urioste, M., Benitez, J., Boix-Chornet, M., Sanchez-Aguilera, A., Ling, C., Carlsson, E., Poulsen, P., Vaag, A., Stephan, Z., Spector, T.D., Wu, Y.Z., Plass, C. and Esteller, M. (2005) Epigenetic Differences Arise during the Lifetime of Monozygotic Twins. Proceedings of the National Academy of Sciences of the United States of America, 102, 10604-10609.
[100] Wong, A.H., Gottesman, I.I. and Petronis, A. (2005) Phenotypic Differences in Genetically Identical Organisms: The Epigenetic Perspective. Human Molecular Genetics, 14, R11-R18.
[101] Bruder, C.E., Piotrowski, A., Gijsbers, A.A., Andersson, R., Erickson, S., de Stahl, T.D., Menzel, U., Sandgren, J., von Tell, D., Poplawski, A., Crowley, M., Crasto, C., Partridge, E.C., Tiwari, H., Allison, D.B., Komorowski, J., van Ommen, G.J., Boomsma, D.I., Pedersen, N.L., den Dunnen, J.T., Wirdefeldt, K. and Dumanski, J.P. (2008) Phenotypically Concordant and Discordant Monozygotic Twins Display Different DNA Copy-Number-Variation Profiles. American Journal of Human Genetics, 82, 763-771.
[102] Muqit, M.M., Larner, A.J., Sweeney, M.G., Sewry, C., Stinton, V.J., Davis, M.B., Healy, D.G., Payne, S.J., Chotai, K., Wood, N.W. and Lane, R.J. (2008) Multiple Mitochondrial DNA Deletions in Monozygotic Twins with OPMD. Journal of Neurology, Neurosurgery Psychiatry, 79, 68-71.
[103] Javierre, B.M., Fernandez, A.F., Richter, J., Al-Shahrour, F., Martin-Subero, J.I., Rodriguez-Ubreva, J., Berdasco, M., Fraga, M.F., O’Hanlon, T.P., Rider, L.G., Jacinto, F.V., Lopez-Longo, F.J., Dopazo, J., Forn, M., Peinado, M.A., Carreno, L., Sawalha, A.H., Harley, J.B., Siebert, R., Esteller, M., Miller, F.W. and Ballestar, E. (2010) Changes in the Pattern of DNA Methylation Associate with Twin Discordance in Systemic Lupus Erythematosus. Genome Research, 20, 170-179.
[104] Misch, E.A., Berrington, W.R., Vary Jr., J.C. and Hawn, T.R. (2010) Leprosy and the Human Genome. Microbiology and Molecular Biology Reviews: MMBR, 74, 589-620.
[105] Stankiewicz, P. and Lupski, J.R. (2010) Structural Variation in the Human Genome and Its Role in Disease. Annual Review of Medicine, 61, 437-455.
[106] Bell, J.T. and Spector, T.D. (2011) A Twin Approach to Unraveling Epigenetics. Trends in Genetics: TIG, 27, 116-125.
[107] Dempster, E.L., Pidsley, R., Schalkwyk, L.C., Owens, S., Georgiades, A., Kane, F., Kalidindi, S., Picchioni, M., Kravariti, E., Toulopoulou, T., Murray, R.M. and Mill, J. (2011) Disease-Associated Epigenetic Changes in Monozygotic Twins Discordant for Schizophrenia and Bipolar Disorder. Human Molecular Genetics, 20, 4786-4796.
[108] Gordon, L., Joo, J.H., Andronikos, R., Ollikainen, M., Wallace, E.M., Umstad, M.P., Permezel, M., Oshlack, A., Morley, R., Carlin, J.B., Saffery, R., Smyth, G.K. and Craig, J.M. (2011) Expression Discordance of Monozygotic Twins at Birth: Effect of Intrauterine Environment and a Possible Mechanism for Fetal Programming. Epigenetics, 6, 579-592.
[109] Maiti, S., Kumar, K.H.B.G., Castellani, C.A., O’Reilly, R. and Singh, S.M. (2011) Ontogenetic de Novo Copy Number Variations (CNVs) as a Source of Genetic Individuality: Studies on Two Families with MZD Twins for Schizophrenia. PLoS ONE, 6, e17125.
[110] Ollikainen, M. and Craig, J.M. (2011) Epigenetic Discordance at Imprinting Control Regions in Twins. Epigenomics, 3, 295-306.
[111] Chapman, S.J. and Hill, A.V.S. (2012) Human Genetic Susceptibility to Infectious Disease. Nature Reviews Genetics, 13, 175-188.
[112] Czyz, W., Morahan, J., Ebers, G. and Ramagopalan, S. (2012) Genetic, Environmental and Stochastic Factors in Monozygotic Twin Discordance with a Focus on Epigenetic Differences. BMC Medicine, 10, 93.
[113] Halder, A., Jain, M., Chaudhary, I. and Varma, B. (2012) Chromosome 22q11.2 Microdeletion in Monozygotic Twins with Discordant Phenotype and Deletion Size. Molecular Cytogenetics, 5, 13.
[114] Zhao, J., Goldberg, J., Bremner, J.D. and Vaccarino, V. (2012) Global DNA Methylation Is Associated with Insulin Resistance: A Monozygotic Twin Study. Diabetes, 61, 542-546.
[115] Litchfield Jr., J.T. (1962) Symposium on Clinical Drug Evaluation and Human Pharmacology. XVI. Evaluation of the Safety of New Drugs by Means of Tests in Animals. Clinical Pharmacology Therapeutics, 3, 665-672.
[116] Smith, R.L. and Caldwell, J. (1977) Drug Metabolism in Non-Human Primates. In: Parke, D.V. and Smith, R.L., Eds., Drug Metabolism—From Microbe to Man, Taylor & Francis, London, 331-356.
[117] Fletcher, A.P. (1978) Drug Safety Tests and Subsequent Clinical Experience. Journal of the Royal Society of Medicine, 71, 693-696.
[118] Ennever, F.K., Noonan, T.J. and Rosenkranz, H.S. (1987) The Predictivity of Animal Bioassays and Short-Term Genotoxicity Tests for Carcinogenicity and Non-Carcinogenicity to Humans. Mutagenesis, 2, 73-78.
[119] Lumley, C. (1990) Clinical Toxicity: Could It Have Been Predicted? Premarketing Experience. In: Lumley, C. and Walker, S. Eds., Animal Toxicity Studies: Their Relevance for Man, Quay, London, 49-56.
[120] Suter, K. (1990) What Can Be Learned from Case Studies? The Company Approach. In: Lumley, C. and Walker, S., Eds., Animal Toxicity Studies: Their Relevance for Man, Quay, Lancaster, 71-78.
[121] Spriet-Pourra, C. and Auriche, M. (1994) SCRIP Reports. PJB Publications, New York.
[122] Igarashi, T., Nakane, S. and Kitagawa, T. (1995) Predictability of Clinical Adverse Reactions of Drugs by General Pharmacology Studies. Journal of Toxicological Sciences, 20, 77-92.
[123] Igarashi, T., Yabe, T. and Noda, K. (1996) Study Design and Statistical Analysis of Toxicokinetics: A Report of JPMA Investigation of Case Studies. Journal of Toxicological Sciences, 21, 497-504.
[124] Chiou, W.L., Jeong, H.Y., Chung, S.M. and Wu, T.C. (2000) Evaluation of Using Dog as an Animal Model to Study the Fraction of Oral Dose Absorbed of 43 Drugs in Humans. Pharmaceutical Research, 17, 135-140.
[125] Mahmood, I. (2000) Can Absolute Oral Bioavailability in Humans Be Predicted from Animals? A Comparison of Allometry and Different Indirect Methods. Drug Metabolism and Drug Interactions, 16, 143-155.
[126] Johnson, J.I., Decker, S., Zaharevitz, D., Rubinstein, L.V., Venditti, J.M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M. and Sausville, E.A. (2001) Relationships between Drug Activity in NCI Preclinical in Vitro and in Vivo Models and Early Clinical Trials. British Journal of Cancer, 84, 1424-1431.
[127] Grass, G.M. and Sinko, P.J. (2002) Physiologically-Based Pharmacokinetic Simulation Modelling. Advanced Drug Delivery Reviews, 54, 433-451.
[128] Weaver, J.L., Staten, D., Swann, J., Armstrong, G., Bates, M. and Hastings, K.L. (2003) Detection of Systemic Hypersensitivity to Drugs Using Standard Guinea Pig Assays. Toxicology, 193, 203-217.
[129] FDA (2004) Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products.
[130] Kola, I. and Landis, J. (2004) Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Reviews Drug Discovery, 3, 711-715.
[131] Lesko, L.J. and Woodcock, J. (2004) Translation of Pharmacogenomics and Pharmacogenetics: A Regulatory Perspective. Nature Reviews Drug Discovery, 3, 763-769.
[132] Shepard, T. and Lemire, R. (2004) Catalog of Teratogenic Agents. 11th Edition. Johns Hopkins, Baltimore.
[133] Kummar, S., Kinders, R., Rubinstein, L., Parchment, R.E., Murgo, A.J., Collins, J., Pickeral, O., Low, J., Steinberg, S.M., Gutierrez, M., Yang, S., Helman, L., Wiltrout, R., Tomaszewski, J.E. and Doroshow, J.H. (2007) Compressing Drug Development Timelines in Oncology Using Phase “0” Trials. Nature Reviews. Cancer, 7, 131-139.
[134] Hughes, B. (2008) Industry Concern over EU Hepatotoxicity Guidance. Nature Reviews Drug Discovery, 7, 719-719.
[135] Arrowsmith, J. (2011) Trial Watch: Phase III and Submission Failures: 2008-2010. Nature Reviews Drug Discovery, 10, 87-87.
[136] Arrowsmith, J. (2011) Trial Watch: Phase II Failures: 2008-2010. Nature Reviews Drug Discovery, 10, 328-329.
[137] Morgan, P., Graaf, P.H.V.D., Arrowsmith, J., Feltner, D.E., Drummond, K.S., Wegner, C.D. and Street, S.D.A. (2012) Can the Flow of Medicines Be Improved? Fundamental Pharmacokinetic and Pharmacological Principles toward Improving Phase II Survival. Drug Discovery Today, 17, 419-424.
[138] van Meer, P.J.K., Kooijman, M., Gispen-de Wied, C.C., Moors, E.H.M. and Schellekens, H. (2012) The Ability of Animal Studies to Detect Serious Post Marketing Adverse Events Is Limited. Regulatory Toxicology and Pharmacology, 64, 345-349.
[139] Seok, J., Warren, H.S., Cuenca, A.G., Mindrinos, M.N., Baker, H.V., Xu, W., Richards, D.R., McDonald-Smith, G.P., Gao, H., Hennessy, L., Finnerty, C.C., Lopez, C.M., Honari, S., Moore, E.E., Minei, J.P., Cuschieri, J., Bankey, P.E., Johnson, J.L., Sperry, J., Nathens, A.B., Billiar, T.R., West, M.A., Jeschke, M.G., Klein, M.B., Gamelli, R.L., Gibran, N.S., Brownstein, B.H., Miller-Graziano, C., Calvano, S.E., Mason, P.H., Cobb, J.P., Rahme, L.G., Lowry, S.F., Maier, R.V., Moldawer, L.L., Herndon, D.N., Davis, R.W., Xiao, W. and Tompkins, R.G. (2013) Genomic Responses in Mouse Models Poorly Mimic Human Inflammatory Diseases. Proceedings of the National Academy of Sciences of the United States of America, 110, 3507-3512.
[140] Buchbinder, S.P., Mehrotra, D.V., Duerr, A., Fitzgerald, D.W., Mogg, R., Li, D., Gilbert, P.B., Lama, J.R., Marmor, M., Del Rio, C., McElrath, M.J., Casimiro, D.R., Gottesdiener, K.M., Chodakewitz, J.A., Corey, L. and Robertson, M.N. (2008) Efficacy Assessment of a Cell-Mediated Immunity HIV-1 Vaccine (the Step Study): A Double-Blind, Randomised, Placebo-Controlled, Test-of-Concept Trial. Lancet, 372, 1881-1893.
[141] Editorial (2007) Cold Shower for AIDS Vaccines. Nature Medicine, 13, 1389-1390.
[142] Gamble, L.J. and Matthews, Q.L. (2010) Current Progress in the Development of a Prophylactic Vaccine for HIV-1. Drug Design, Development and Therapy, 5, 9-26.
[143] Cheng, Y.D., Al-Khoury, L. and Zivin, J.A. (2004) Neuroprotection for Ischemic Stroke: Two Decades of Success and Failure. NeuroRx, 1, 36-45.
[144] Curry, S.H. (2003) Why Have So Many Drugs with Stellar Results in Laboratory Stroke Models Failed in Clinical Trials? A Theory Based on Allometric Relationships. Annals of the New York Academy of Sciences, 993, 69-74.
[145] Faden, A.I. (2002) Neuroprotection and Traumatic Brain Injury: Theoretical Option or Realistic Proposition. Current Opinion in Neurology, 15, 707-712.
[146] Faden, A.I. and Stoica, B. (2007) Neuroprotection: Challenges and Opportunities. Archives of Neurology, 64, 794-800.
[147] Feuerstein, G.Z. and Chavez, J. (2009) Translational Medicine for Stroke Drug Discovery: The Pharmaceutical Industry Perspective. Stroke, 40, S121-S125.
[148] Gilligan, A.K., Thrift, A.G., Sturm, J.W., Dewey, H.M., Macdonell, R.A. and Donnan, G.A. (2005) Stroke Units, Tissue Plasminogen Activator, Aspirin and Neuroprotection: Which Stroke Intervention Could Provide the Greatest Community Benefit? Cerebrovascular Diseases, 20, 239-244.
[149] Ginsberg, M.D. (2008) Neuroprotection for Ischemic Stroke: Past, Present and Future. Neuropharmacology, 55, 363-389.
[150] Grotta, J. (2002) Neuroprotection Is Unlikely to Be Effective in Humans Using Current Trial Designs. Stroke, 33, 306-307.
[151] Macleod, M. (2004) Systematic Review and Meta-Analysis of Experimental Stroke. International Journal of Neuroprotection and Neuroregeneration, 1, 9-12.
[152] O’Collins, V.E., Macleod, M.R., Cox, S.F., Van Raay, L., Aleksoska, E., Donnan, G.A. and Howells, D.W. (2011) Preclinical Drug Evaluation for Combination Therapy in Acute Stroke Using Systematic Review, Meta-Analysis, and Subsequent Experimental Testing. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 31, 962-975.
[153] Plum, F. (2001) Neuroprotection in Acute Ischemic Stroke. JAMA, 285, 1760-1761.
[154] Horstmann, D. (1985) The Poliomyelitis Story; a Scientific Hegira. Yale Journal of Biology and Medicine, 58, 79-90.
[155] Oshinsky, D.M. (2005) Polio: An American Story. Oxford University Press.
[156] Paul, J.R. (1971) A History of Poliomyelitis. Yale University Press, New Haven.
[157] Smith, W.E., Miller, L., Elsasser, R.E. and Hubert, D.D. (1965) Tests for Carcinogenicity of Asbestos. Annals of the New York Academy of Sciences, 132, 456-488.
[158] Royal Society of Medicine (1980) Successes, Failures and Hopes in Cancer Chemotherapy. Proceedings of an International Symposium by the Royal Society of Medicine, Medico-Pharmaceutical Forum, London.
[159] Sitaram, N. and Gershon, S. (1983) From Animal Models to Clinical Testing—Promises and Pitfalls. Progress in Neuro-Psychopharmacology Biological Psychiatry, 7, 227-228.
[160] Sietsema, W.K. (1989) The Absolute Oral Bioavailability of Selected Drugs. International Journal of Clinical Pharmacology, Therapy and Toxicology, 27, 179-211.
[161] Eason, C.T., Bonner, F.W. and Parke, D.V. (1990) The Importance of Pharmacokinetic and Receptor Studies in Drug Safety Evaluation. Regulatory Toxicology and Pharmacology, 11, 288-307.
[162] Heywood, R. (1990) Clinical Toxicity—Could It Have Been Predicted? Post-Marketing Experience. In: Lumley, C.E. and Walker, S. Eds., Animal Toxicity Studies: Their Relevance for Man, Quay, Lancaster, 57-67.
[163] Calabrese, E.J. (1991) Principles of Animal Extrapolation. CRC Press, Boca Raton.
[164] Lin, J.H. (1995) Species Similarities and Differences in Pharmacokinetics. Drug Metabolism and Disposition, 23, 1008-1021.
[165] Connors, T. (1996) Anticancer Drug Development: The Way Forward. Oncologist, 1, 180-181.
[166] Gura, T. (1997) Cancer Models: Systems for Identifying New Drugs Are Often Faulty. Science, 278, 1041-1042.
[167] Meijers, J.M., Swaen, G.M. and Bloemen, L.J. (1997) The Predictive Value of Animal Data in Human Cancer Risk Assessment. Regulatory Toxicology and Pharmacology, 25, 94-102.
[168] Noble, M. (2000) Can Neural Stem Cells Be Used as Therapeutic Vehicles in the Treatment of Brain Tumors? Nature Medicine, 6, 369-370.
[169] van Zutphen, L.F. (2000) Is There a Need for Animal Models of Human Genetic Disorders in the Post-Genome Era? CompMed, 50, 10-11.
[170] Alving, C.R. (2002) Design and Selection of Vaccine Adjuvants: Animal Models and Human Trials. Vaccine, 20, S56-S64.
[171] Barnes, J.C. and Hayes, A.G. (2002) CNS Drug Discovery: Realising the Dream. Drug Discovery World, 54-57.
[172] Palfreyman, M.G., Charles, V. and Blander, J. (2002) The Importance of Using Human-Based Models in Gene and Drug Discovery. Drug Discovery World, 33-40.
[173] Duyk, G. (2003) Attrition and Translation. Science, 302, 603-605.
[174] Horrobin, D.F. (2003) Modern Biomedical Research: An Internally Self-Consistent Universe with Little Contact with Medical Reality? Nature Reviews Drug Discovery, 2, 151-154.
[175] Höerig, H. and Pullman, W. (2004) From Bench to Clinic and Back: Perspective on the 1st IQPC Translational Research Conference. Journal of Translational Medicine, 2, 44.
[176] Seligmann, B. (2004/5) Gene Expression as a Toxicological Screening Tool. The Use of Microarray Data in Drug Development and Requirements for FDA Audit and Approval. Drug Discovery World, 77-83.
[177] Abbott, A. (2005) Animal Testing: More than a Cosmetic Change. Nature, 438, 144-146.
[178] Butcher, E.C. (2005) Can Cell Systems Biology Rescue Drug Discovery? Nature Reviews Drug Discovery, 4, 461-467.
[179] Chabner, B.A. and Roberts Jr., T.G. (2005) Timeline: Chemotherapy and the War on Cancer. Nature Reviews Cancer, 5, 65-72.
[180] Editorial (2005) The Time Is Now. Nature Reviews Drug Discovery, 4, 613.
[181] Kamb, A. (2005) What’s Wrong with Our Cancer Models? Nature Reviews Drug Discovery, 4, 161-165.
[182] Littman, B.H. and Williams, S.A. (2005) The Ultimate Model Organism: Progress in Experimental Medicine. Nature Reviews Drug Discovery, 4, 631-638.
[183] Abate-Shen, C. (2006) A New Generation of Mouse Models of Cancer for Translational Research. Clinical Cancer Research, 12, 5274-5276.
[184] Dennis, C. (2006) Cancer: Off by a Whisker. Nature, 442, 739-741.
[185] FDA (2006) FDA Issues Advice to Make Earliest Stages of Clinical Drug Development More Efficient.
[186] Hurko, O. (2006) Understanding the Strategic Importance of Biomarkers for the Discovery and Early Development Phases. Drug Discovery World, 63-74.
[187] McGee, P. (2006) Breeding Better Animal Models. Drug Discovery & Development, 18-23.
[188] O’Collins, V.E., Macleod, M.R., Donnan, G.A., Horky, L.L., van der Worp, B.H. and Howells, D.W. (2006) 1,026 Experimental Treatments in Acute Stroke. Annals of Neurology, 59, 467-477.
[189] Björquist, P., Sartipy, P., Strehl, R. and Hyllner, J. (2007) Human ES Cell Derived Functional Cells as Tools in Drug Discovery. Drug Discovery World, 17-24.
[190] Dixit, R. and Boelsterli, U. (2007) Healthy Animals and Animal Models of Human Disease(s) in Safety Assessment of Human Pharmaceuticals, including Therapeutic Antibodies. Drug Discovery Today, 12, 336-342.
[191] Loisel, S., Ohresser, M., Pallardy, M., Dayde, D., Berthou, C., Cartron, G. and Watier, H. (2007) Relevance, Advantages and Limitations of Animal Models Used in the Development of Monoclonal Antibodies for Cancer Treatment. Critical Reviews in Oncology/Hematology, 62, 34-42.
[192] Alini, M., Eisenstein, S.M., Ito, K., Little, C., Kettler, A.A., Masuda, K., Melrose, J., Ralphs, J., Stokes, I. and Wilke, H.J. (2008) Are Animal Models Useful for Studying Human Disc Disorders/Degeneration? European Spine Journal, 17, 2-19.
[193] Bendtsen, F. and Moller, S. (2008) Pharmacological Effects Are Model Specific in Animal Models of Portal Hypertension. Hepatology International, 2, 397-398.
[194] Dragunow, M. (2008) The Adult Human Brain in Preclinical Drug Development. Nature Reviews Drug Discovery, 7, 659-666.
[195] Matthews, R.A. (2008) Medical Progress Depends on Animal Models—Doesn’t It? Journal of the Royal Society of Medicine, 101, 95-98.
[196] Wall, R.J. and Shani, M. (2008) Are Animal Models as Good as We Think? Theriogenology, 69, 2-9.
[197] Young, M. (2008) Prediction v Attrition. Drug Discovery World, 9-12.
[198] Enna, S.J. and Williams, M. (2009) Defining the Role of Pharmacology in the Emerging World of Translational Research. Advances in Pharmacology, 57, 1-30.
[199] Geerts, H. (2009) Of Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery. CNS Drugs, 23, 915-926.
[200] Markou, A., Chiamulera, C., Geyer, M.A., Tricklebank, M. and Steckler, T. (2009) Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 34, 74-89.
[201] Regenberg, A., Mathews, D.J., Blass, D.M., Bok, H., Coyle, J.T., Duggan, P., Faden, R., Finkel, J., Gearhart, J.D., Hillis, A., Hoke, A., Johnson, R., Johnston, M., Kahn, J., Kerr, D., King, P., Kurtzberg, J., Liao, S.M., McDonald, J.W., McKhann, G., Nelson, K.B., Rao, M., Siegel, A.W., Smith, K., Solter, D., Song, H., Sugarman, J., Vescovi, A., Young, W., Greely, H.T. and Traystman, R.J. (2009) The Role of Animal Models in Evaluating Reasonable Safety and Efficacy for Human Trials of Cell-Based Interventions for Neurologic Conditions. Journal of Cerebral Blood Flow Metabolism, 29, 1-9.
[202] Taylor, D.L. (2009) Human vs Rodent. Drug Discovery & Development, 12, 16-18.
[203] Brennan, R., Federico, S. and Dyer, M.A. (2010) The War on Cancer: Have We Won the Battle but Lost the War? Oncotarget, 1, 77-83.
[204] Editorial (2010) Learning from Failure. Nature Reviews Drug Discovery, 9, 499-499.
[205] Hait, W.N. (2010) Anticancer Drug Development: The Grand Challenges. Nature Reviews Drug Discovery, 9, 253-254.
[206] Hampel, H., Frank, R., Broich, K., Teipel, S.J., Katz, R.G., Hardy, J., Herholz, K., Bokde, A.L.W., Jessen, F., Hoessler, Y.C., Sanhai, W.R., Zetterberg, H., Woodcock, J. and Blennow, K. (2010) Biomarkers for Alzheimer’s Disease: Academic, Industry and Regulatory Perspectives. Nature Reviews Drug Discovery, 9, 560-574.
[207] M.E. (2010) In This Issue. Models That Better Mimic Human Cancer. Nature Biotechnology, 28, vii.
[208] Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R. and Schacht, A.L. (2010) How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge. Nature Reviews Drug Discovery, 9, 203-214.
[209] Zhang, Q., Bhattacharya, S., Andersen, M.E. and Conolly, R.B. (2010) Computational Systems Biology and Dose-Response Modeling in Relation to New Directions in Toxicity Testing. Journal of Toxicology and Environmental Health. Part B, Critical Reviews, 13, 253-276.
[210] Zielinska, E. (2010) Building a Better Mouse. The Scientist, 24, 34-38.
[211] Chapman, A.R. (2011) Addressing the Ethical Challenges of First-in-Human Trials. Journal of Clinical Research Bioethics, 2, 113.
[212] Collins, F.S. (2011) Reengineering Translational Science: The Time Is Right. Science Translational Medicine, 3, Article ID: 90cm17.
[213] Elferink, M.G.L., Olinga, P., van Leeuwen, E.M., Bauerschmidt, S., Polman, J., Schoonen, W.G., Heisterkamp, S.H. and Groothuis, G.M.M. (2011) Gene Expression Analysis of Precision-Cut Human Liver Slices Indicate Stable Expression of ADME-Tox Related Genes. Toxicology and Applied Pharmacology, Accepted Manuscript.
[214] Engber, D. (2011) Lab Mice: Are They Limiting Our Understanding of Human Disease?
[215] Force, T. and Kolaja, K.L. (2011) Cardiotoxicity of Kinase Inhibitors: The Prediction and Translation of Preclinical Models to Clinical Outcomes. Nature Reviews Drug Discovery, 10, 111-126.
[216] Giri, S. and Bader, A. (2011) Foundation Review: Improved Preclinical Safety Assessment Using Micro-BAL Devices: The Potential Impact on Human Discovery and Drug Attrition. Drug Discovery Today, 16, 382-397.
[217] Holmes, A.M., Solari, R. and Holgate, S.T. (2011) Animal Models of Asthma: Value, Limitations and Opportunities for Alternative Approaches. Drug Discovery Today, 16, 659-670.
[218] Kay, M.A. (2011) State-of-the-Art Gene-Based Therapies: The Road Ahead. Nature Reviews Genetics, 12, 316-328.
[219] Lutz, D. (2011) New Study Calls into Question Reliance on Animal Models in Cardiovascular Research.
[220] McArthur, R. (2011) Editorial: Many Are Called Yet Few Are Chosen. Are Neuropsychiatric Clinical Trials Letting Us Down? Drug Discovery Today, 16, 173-175.
[221] Mullard, A. (2011) Marc Kirschner. Nature Reviews Drug Discovery, 10, 894-894.
[222] News & Analysis (2011) News in Brief. Nature Reviews Drug Discovery, 10, 889-889.
[223] Reuters (2011) U.S. to Develop Chip That Tests If a Drug Is Toxic.
[224] Sharp, P.A. and Langer, R. (2011) Promoting Convergence in Biomedical Science. Science, 333, 527.
[225] Cook, N., Jodrell, D.I. and Tuveson, D.A. (2012) Predictive in Vivo Animal Models and Translation to Clinical Trials. Drug Discovery Today, 17, 253-260.
[226] Drake III, D.R., Singh, I., Nguyen, M.N., Kachurin, A., Wittman, V., Parkhill, R., Kachurina, O., Moser, J.M., Burdin, N., Moreau, M., Mistretta, N., Byers, A.M., Dhir, V., Tapia, T.M., Vernhes, C., Gangur, J., Kamala, T., Swaminathan, N. and Warren, W.L. (2012) In Vitro Biomimetic Model of the Human Immune System for Predictive Vaccine Assessments. Disruptive Science and Technology, 1, 28-40.
[227] Herper, M. (2012) Can Bush’s NIH Chief Fix the Drug Industry?
[228] Khanna, I. (2012) Drug Discovery in Pharmaceutical Industry: Productivity Challenges and Trends. Drug Discovery Today, 17, 1088-1102.
[229] Ledford, H. (2012) Success through Cooperation.
[230] Marusina, K. (2012) Animal Models Get Closer to Mimicking Humans.
[231] Millan, M.J., Agid, Y., Brune, M., Bullmore, E.T., Carter, C.S., Clayton, N.S., Connor, R., Davis, S., Deakin, B., Derubeis, R.J., Dubois, B., Geyer, M.A., Goodwin, G.M., Gorwood, P., Jay, T.M., Joels, M., Mansuy, I.M., Meyer-Lindenberg, A., Murphy, D., Rolls, E., Saletu, B., Spedding, M., Sweeney, J., Whittington, M. and Young, L.J. (2012) Cognitive Dysfunction in Psychiatric Disorders: Characteristics, Causes and the Quest for Improved Therapy. Nature Reviews. Drug Discovery, 11, 141-168.
[232] Mullane, K. and Williams, M. (2012) Translational Semantics and Infrastructure: Another Search for the Emperor’s New Clothes? Drug Discovery Today, 17, 459-468.
[233] Neuzil, P., Giselbrecht, S., Lange, K., Huang, T.J. and Manz, A. (2012) Revisiting Lab-on-a-Chip Technology for Drug Discovery. Nature Reviews. Drug Discovery, 11, 620-632.
[234] Opar, A. (2012) Overtaking the DILI Model-T. Nature Reviews Drug Discovery, 11, 585-586.
[235] Prater, D.A. (2012) Development and Use of Advanced Testing Approaches by the U.S. FDA.
[236] Raven, K. (2012) Rodent Models of Sepsis Found Shockingly Lacking. Nature Medicine, 18, 998-998.
[237] Rice, J. (2012) Animal Models: Not Close Enough. Nature, 484, S9.
[238] Shaffer, C. (2012) Safety through Sequencing.
[239] Taneja, A., Di Iorio, V.L., Danhof, M. and Della Pasqua, O. (2012) Translation of Drug Effects from Experimental Models of Neuropathic Pain and Analgesia to Humans. Drug Discovery Today, 17, 837-849.
[240] Uhl, E.W., Whitley, E., Galbreath, E., McArthur, M. and Oglesbee, M.J. (2012) Evolutionary Aspects of Animal Models. Veterinary Pathology, 49, 876-878.
[241] Fernandes, P. and Vali, S. (2012) Predicting Pathway Effects.
[242] Sarter, M. and Tricklebank, M. (2012) Revitalizing Psychiatric drug Discovery. Nature Reviews Drug Discovery, 11, 423-424.
[243] Griebel, G. and Holsboer, F. (2012) Neuropeptide Receptor Ligands as Drugs for Psychiatric Diseases: The End of the Beginning? Nature Reviews Drug Discovery, 11, 462-478.
[244] Tallman, J.F. (1999) Neuropsychopharmacology at the New Millennium: New Industry Directions. Neuropsychopharmacology, 20, 99-105.
[245] Davis, M.M. (2008) A Prescription for Human Immunology. Immunity, 29, 835-838.
[246] MacDonald, J.S. and Robertson, R.T. (2009) Toxicity Testing in the 21st Century: A View from the Pharmaceutical Industry. Toxicological Sciences: An Official Journal of the Society of Toxicology, 110, 40-46.
[247] FDA (2011) Advancing Regulatory Science at FDA: A Strategic Plan.
[248] Hamburg, M.A. (2011) Advancing Regulatory Science. Science, 331, 987.
[249] Community Corner (2012) A Step Closer to Effective Transplant Tolerance? Nature Medicine, 18, 664-665.
[250] McManus, R. (2013) Ex-Director Zerhouni Surveys Value of NIH Research.
[251] Scannell, J.W., Blanckley, A., Boldon, H. and Warrington, B. (2012) Diagnosing the Decline in Pharmaceutical R&D Efficiency. Nature Reviews Drug Discovery, 11, 191-200.
[252] Suggitt, M. and Bibby, M.C. (2005) 50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 11, 971-981.
[253] Committee on Revising Science and Creationism (2008) Science, Evolution, and Creationism. National Academy of Sciences, Washington DC.
[254] American Association for the Advancement of Science (2011) Q & A on Evolution and Intelligent Design.
[255] Popper, K. (2002) Conjectures and Refutations: The Growth of Scientific Knowledge. 2nd Edition, Routledge Classics, Routledge, New York.
[256] Patz, J.A., McGeehin, M.A., Bernard, S.M., Ebi, K.L., Epstein, P.R., Grambsch, A., Gubler, D.J., Reither, P., Romieu, I., Rose, J.B., Samet, J.M. and Trtanj, J. (2000) The Potential Health Impacts of Climate Variability and Change for the United States: Executive Summary of the Report of the Health Sector of the U.S. National Assessment. Environmental Health Perspectives, 108, 367-376.
[257] Feenstra, J.F., Burton, I., Smith, J.B. and Tol, R.S.J. (1998) Handbook on Methods for Climate Change Impact Assessment and Adaptation Strategies.
[258] Barber, B. (1961) Resistance by Scientists to Scientific Discovery. Science, 134, 596-602.
[259] abpi (2013) Infectious Diseases—Timeline.
[260] Gad, S. (2007) Preface. In: Gad, S., Ed., Animal Models in Toxicology, CRC Press, Boca Raton, 1-18.
[261] Campbell, D. (2012) Public Opposition to Animal Testing Grows.
[262] Hart, B.A., Abbott, D.H., Nakamura, K. and Fuchs, E. (2012) The Marmoset Monkey: A Multi-Purpose Preclinical and Translational Model of Human Biology and Disease. Drug Discovery Today, 17, 1160-1165.
[263] Gibson, E. (2012) Q&A: Dr. Keith Cheng, Researcher at Penn State’s College of Medicine, Shares Views on Using Animals in Scientific Research.
[264] Vassar, R. (2011) Alzheimer’s Therapy: A BACE in the Hand? Nature Medicine, 17, 932-933.
[265] Thorstensson, R. (2006) Medicinska försök på apor är inget etiskt problem för mig (Medical research on apes is no ethical problem for me). Infectious Diseases, Kronikor.
[266] Rudczynski, A.B. (2011) Letter. New Haven Register, New Haven.
[267] Hau, J. (2003) Animal Models. In: Hau, J. and van Hoosier Jr., G.K., Eds., Handbook of Laboratory Animal Science, 2nd Edition, Animal Models, CRC Press, Boca Raton, 1-9.
[268] Committee on Applications of Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment, N.R.C. (2007) Applications of Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment. National Academy of Sciences, Washington DC.
[269] Editors (2011) In This Issue. Nature Reviews Drug Discovery, 10, 239.
[270] Mankoff, S.P., Brander, C., Ferrone, S. and Marincola, F.M. (2004) Lost in Translation: Obstacles to Translational Medicine. Journal of Translational Medicine, 2, 14.
[271] Schreiber, S.L., Shamji, A.F., Clemons, P.A., Hon, C., Koehler, A.N., Munoz, B., Palmer, M., Stern, A.M., Wagner, B.K., Powers, S., Lowe, S.W., Guo, X., Krasnitz, A., Sawey, E.T., Sordella, R., Stein, L., Trotman, L.C., Califano, A., Dalla-Favera, R., Ferrando, A., Iavarone, A., Pasqualucci, L., Silva, J., Stockwell, B.R., Hahn, W.C., Chin, L., DePinho, R.A., Boehm, J.S., Gopal, S., Huang, A., Root, D.E., Weir, B.A., Gerhard, D.S., Zenklusen, J.C., Roth, M.G., White, M.A., Minna, J.D., MacMillan, J.B. and Posner, B.A. (2010) Towards Patient-Based Cancer Therapeutics. Nature Biotechnology, 28, 904-906.
[272] Riveros, C., Dechartres, A., Perrodeau, E., Haneef, R., Boutron, I. and Ravaud, P. (2013) Timing and Completeness of Trial Results Posted at and Published in Journals. PLoS Medicine, 10, Article ID: e1001566.
[273] McBride, W. (1961) Letter. Thalidomide and Congential Abnormalities. Lancet, 278, 1358.
[274] Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B. and Heller, A. (2000) Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals. Regulatory Toxicology and Pharmacology, 32, 56-67.
[275] Oesterhelweg, L., Krober, S., Rottmann, K., Willhoft, J., Braun, C., Thies, N., Puschel, K., Silkenath, J. and Gehl, A. (2008) Cadaver Dogs—A Study on Detection of Contaminated Carpet Squares. Forensic Science International, 174, 35-39.
[276] Davis, H. (1988) The Accuracy of Industry Data from Death Certificates for Workplace Homicide Victims. American Journal of Public Health, 78, 1579-1581.
[277] Buchanich, J.M., Youk, A.O., Marsh, G.M., Kennedy, K.J., Esmen, N.A., Lacey, S.E., Hancock, R., Cunningham, M.A., Lieberman, F.S. and Fleissner, M.L. (2010) Long-Term Health Experience of Jet Engine Manufacturing Workers: IV. A Comparison of Central Nervous System Cancer Ascertainment Using Mortality and Incidence Data. Annals of Epidemiology, 20, 759-765.
[278] Cocco, P. (2012) Advances in the Retrospective Assessment of Occupational Exposures: Results from the European Case-Control Study EPILYMPH.
[279] Holloway, M. and Nwaoha, C. (2012) Dictionary of Industrial Terms. Wiley, John & Sons, Incorporated, London.
[280] Roy, S., Sajeev, A.S.M., Bihary, S. and Ranjan, A. (2011) An Empirical Study of Error Patterns in Industrial Business Process Models. IEEE Transactions on Services Computing.
[281] Karwowski, W. (2001) The Strain Index. In: Karwowski, W., Ed., International Encyclopedia of Ergonomics and Human Factors, CRC Press, Boca Rotan, 1600.
[282] Dhandayudam, P. and Krishnamurthi, I. (2013) Customer Behavior Analysis Using Rough Set Approach. Journal of Theoretical and Applied Electronic Commerce Research, 18.
[283] Clary, C. and Kestens, Y. (2013) Field Validation of Secondary Data Sources: A Novel Measure of Representativity Applied to a Canadian Food Outlet Database. International Journal of Behavioral Nutrition and Physical Activity, 10, 77.
[284] Weiss, S.M., Galen, R.S. and Tadepalli, P.V. (1988) Maximizing the Predictive Value of Production Rules.
[285] Uren, P., Cameron-Jones, R. and Sale, A. (2008) Improving Promoter Prediction Using Mulitple Instance Learning. In: Wobcke, W. and Zhang, M., Eds., AI 2008: Advances in Artificial Intelligence: 21st Australasian Joint Conference on Artificial Intelligence, Auckland, 3-5 December 2008, 289-299.
[286] Mortara (2013) Vision Premier Holter Software.
[287] Barnes, D. (2013) Industry Perspective: Big Data and Big Data Analytics.
[288] Snyder, J. (2011) Comparing Industry-Leading Anti-Spam Services Results from 12 Months of Testing.
[289] Sullivan, J.M., Tsimhoni, O. and Bogard, S. (2007) Warning Reliability and Driver Performance in Naturalistic Driving.
[290] Que, J., Tsui, F.-C. and Espino, J. (2008) A Z-Score Based Multi-Level Spatial Clustering Algorithm for the Detection of Disease Outbreaks. In: Zeng, D., Chen, H., Rolka, H. and Lober, W.B., Eds., Biosurveillance and Biosecurity: International, 108-118.
[291] Almeida, J.D.S., Silva, A.C. and Paiva, A.C. (2011) Automatic Eye Detection in Human Faces Using Geostatistical Functions and Support Vector Machines. In: Kamel, M. and Campilho, A., Eds., Image Analysis and Recognition: 8th International Conference, ICIAR 2011, Burnaby, 22-24 June 2011, 151-160.
[292] Jekel, J.F., Katz, D.L., Wild, D. and Elmore, J.G. (2007) Epidemiology, Biostatistics and Preventive Medicine: With Student Consult Online Access, 3rd Edition, Saunders.
[293] Grimes, D.A. and Schulz, K.F. (2005) Refining Clinical Diagnosis with Likelihood Ratios. The Lancet, 365, 1500-1505.
[294] Altman, D.G. and Bland, J.M. (1994) Diagnostic Tests 2: Predictive Values. BMJ, 309, 102.
[295] Business Dictionary (2013) Evidential Value.
[296] The Law Dictionary (2013) Evidential Value.
[297] Xu, H., Yang, W., Perez-Andreu, V., Devidas, M., Fan, Y., Cheng, C., Pei, D., Scheet, P., Burchard, E.G.l., Eng, C., Huntsman, S., Torgerson, D.G., Dean, M., Winick, N.J., Martin, P.L., Camitta, B.M., Bowman, W.P., Willman, C.L., Carroll, W.L., Mullighan, C.G., Bhojwani, D., Hunger, S.P., Pui, C.-H., Evans, W.E., Relling, M.V., Loh, M.L. and Yang, J.J. (2013) Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute.
[298] Sarkar, M., Bacchetti, P., French, A.L., Tien, P., Glesby, M.J., Nowicki, M., Plankey, M., Gange, S., Sharp, G., Minkoff, H. and Peters, M.G. (2012) Lower Liver-Related Death in African-American Women with Human Immunodeficiency Virus/Hepatitis C Virus Coinfection, Compared to Caucasian and Hispanic Women. Hepatology, 56, 1699-1705.
[299] Abou-Donia, M.B., Lapadula, D.M. and Carrington, C.D. (1988) Biochemical Methods for Assessment of Neurotoxicity. In: Ballantyne, B., Ed., Perspectives in Basic and Applied Toxicology, John Wright, London, 1-30.
[300] Durrant, C., Tayem, H., Yalcin, B., Cleak, J., Goodstadt, L., Pardo-Manuel de Villena, F., Mott, R. and Iraqi, F.A. (2011) Collaborative Cross Mice and Their Power to Map Host Susceptibility to Aspergillus Fumigatus Infection. Genome Research, 21, 1239-1248.
[301] Fleischer, S., Sharkey, M., Mealey, K., Ostrander, E.A. and Martinez, M. (2008) Pharmacogenetic and Metabolic Differences between Dog Breeds: Their Impact on Canine Medicine and the Use of the Dog as a Preclinical Animal Model. AAPS Journal, 10, 110-119.
[302] Herzig, M. and Christofori, G. (2002) Recent Advances in Cancer Research: Mouse Models of Tumorigenesis. Biochimica et Biophysica Acta, 1602, 97-113.
[303] Hunter, K., Welch, D.R. and Liu, E.T. (2003) Genetic Background Is an Important Determinant of Metastatic Potential. Nature Genetics, 34, 23-24.
[304] Ingram, D.K. and Jucker, M. (1999) Developing Mouse Models of Aging: A Consideration of Strain Differences in Age-Related Behavioral and Neural Parameters. Neurobiol Aging, 20, 137-145.
[305] LeCouter, J.E., Kablar, B., Whyte, P.F., Ying, C. and Rudnicki, M.A. (1998) Strain-Dependent Embryonic Lethality in Mice Lacking the Retinoblastoma-Related p130 Gene. Development, 125, 4669-4679.
[306] Lindsay, M.A. (2005) Finding New Drug Targets in the 21st Century. Drug Discovery Today, 10, 1683-1687.
[307] Martinez, M., Modric, S., Sharkey, M., Troutman, L., Walker, L. and Mealey, K. (2008) The Pharmacogenomics of P-Glycoprotein and Its Role in Veterinary Medicine. Journal of Veterinary Pharmacology and Therapeutics, 31, 285-300.
[308] Miklos, G.L.G. (2005) The Human Cancer Genome Project—One More Misstep in the War on Cancer. Nature Biotechnology, 23, 535-537.
[309] Morange, M. (2001) A Successful Form for Reductionism. The Biochemist, 23, 37-39.
[310] Nijhout, H.F. (2003) The Importance of Context in Genetics. American Scientist, 91, 416-423.
[311] Pearson, H. (2002) Surviving a Knockout Blow. Nature, 415, 8-9.
[312] Raineri, I., Carlson, E.J., Gacayan, R., Carra, S., Oberley, T.D., Huang, T.T. and Epstein, C.J. (2001) Strain-Dependent High-Level Expression of a Transgene for Manganese Superoxide Dismutase Is Associated with Growth Retardation and Decreased Fertility. Free Radical Biology Medicine, 31, 1018-1030.
[313] Rohan, R.M., Fernandez, A., Udagawa, T., Yuan, J. and D’Amato, R.J. (2000) Genetic Heterogeneity of Angiogenesis in Mice. FASEB Journal, 14, 871-876.
[314] Sutter, N.B., Bustamante, C.D., Chase, K., Gray, M.M., Zhao, K., Zhu, L., Padhukasahasram, B., Karlins, E., Davis, S., Jones, P.G., Quignon, P., Johnson, G.S., Parker, H.G., Fretwell, N., Mosher, D.S., Lawler, D.F., Satyaraj, E., Nordborg, M., Lark, K.G., Wayne, R.K. and Ostrander, E.A. (2007) A Single IGF1 Allele Is a Major Determinant of Small Size in Dogs. Science, 316, 112-115.
[315] Threadgill, D.W., Dlugosz, A.A., Hansen, L.A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R.C., et al. (1995) Targeted Disruption of Mouse EGF Receptor: Effect of Genetic Background on Mutant Phenotype. Science, 269, 230-234.
[316] Viluksela, M., Duong, T.V., Stahl, B.U., Li, X., Tuomisto, J. and Rozman, K.K. (1996) Toxicokinetics of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) in Two Substrains of Male Long-Evans Rats after Intravenous Injection. Fundamental and Applied Toxicology, 31, 184-191.
[317] Potter, N.E., Ermini, L., Papaemmanuil, E., Cazzaniga, G., Vijayaraghavan, G., Titley, I., Ford, A., Campbell, P., Kearney, L. and Greaves, M. (2013) Single-Cell Mutational Profiling and Clonal Phylogeny in Cancer. Genome Research, 23, 2115-2125.
[318] Jørgensen, J.T. (2011) A Challenging Drug Development Process in the Era of Personalized Medicine. Drug Discovery Today, 16, 891-897.
[319] (1998) Human Albumin Administration in Critically Ill Patients: Systematic Review of Randomised Controlled Trials. Cochrane Injuries Group Albumin Reviewers. BMJ, 317, 235-240.
[320] Finfer, S., Bellomo, R., Boyce, N., French, J., Myburgh, J. and Norton, R. (2004) A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit. New England Journal of Medicine, 350, 2247-2256.
[321] Weinberg, D. (2012) The Plausibility Problem.
[322] Atwood, K. (2008) Prior Probability: The Dirty Little Secret of “Evidence-Based Alternative Medicine”.
[323] Orac (2011) Homeopathy and “Plausibility Bias” versus Science.
[324] Ioannidis, J.P. (2005) Why Most Published Research Findings Are False. PLoS Medicine, 2, e124.
[325] Bayes, T. (1763) An Essay towards Solving a Problem in the Doctrine of Chances. Philosophical Transactions of the Royal Society, 53, 370-418.
[326] Bovens, L. and Hartmann, S. (2004) Bayesian Epistemology. Oxford University Press, New York.
[327] Jørgensen, J.T. (2011) A Challenging Drug Development Process in the Era of Personalized Medicine. Drug Discovery Today, 16, 891-897.
[328] Carrier, R. (2008) “Bayes’ Theorem for Beginners: Formal Logic and Its Relevance to Historical Method—Adjunct Materials and Tutorial”.
[329] Bailey, J. (2008) An Assessment of the Role of Chimpanzees in AIDS Vaccine Research. Alternatives to Laboratory Animals, 36, 381-428.
[330] Kaste, M. (2005) Use of Animal Models Has Not Contributed to Development of Acute Stroke Therapies: Pro. Stroke, 36, 2323-2324.
[331] Sena, E., van der Worp, H.B., Howells, D. and Macleod, M. (2007) How Can We Improve the Pre-Clinical Development of Drugs for Stroke? Trends in Neurosciences, 30, 433-439.
[332] Howells, D.W. and Donnan, G.A. (2010) Where Will the Next Generation of Stroke Treatments Come from? PLoS Medicine, 7, Article ID: e1000224.
[333] Heywood, R. (1981) Target Organ Toxicity. Toxicol Letters, 8, 349-358.
[334] Li, A.P. (2004) Accurate Prediction of Human Drug Toxicity: A Major Challenge in Drug Development. Chemico-Biological Interactions, 150, 3-7.
[335] Spanhaak, S., Cook, D., Barnes, J. and Reynolds, J. (2008) Species Concordance for Liver Injury. From the Safety Intelligence Program Board.
[336] LaFollette, H. and Shanks, N. (1995) Two Models of Models in Biomedical Research. Philosophical Quarterly, 45, 141-160.
[337] LaFollette, H. and Shanks, N. (1996) Brute Science: Dilemmas of Animal Experimentation. Routledge, London and New York.
[338] LaFollette, H. and Shanks, N. (1993) Animal Models in Biomedical Research: Some Epistemological Worries. Public Affairs Quarterly, 7, 113-130.
[339] Committee on Models for Biomedical Research Board on Basic Biology (1985) Committee on Models for Biomedical Research. Board on Basic Biology. Commission on Life Science. National Research Council. Models for Biomedical Research: A New Perspective. National Academy Press, Washington DC.
[340] Platt, J.R. (1964) Strong Inference: Certain Systematic Methods of Scientific Thinking May Produce Much More Rapid Progress than Others. Science, 146, 347-353.
[341] (2002) Drug Discovery & Development, 35.
[342] Roy, A.S.A. (2012) Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials. Project FDA Report, Manhattan Institute for Policy Research, New York.
[343] Sankar, U. (2005) The Delicate Toxicity Balance in Drug Discovery. The Scientist, 19, 32.
[344] Editorial (2006) An Open Debate. Nature, 444, 789-790.
[345] Lazzarini, L., Overgaard, K.A., Conti, E. and Shirtliff, M.E. (2006) Experimental Osteomyelitis: What Have We Learned from Animal Studies about the Systemic Treatment of Osteomyelitis? Journal of Chemotherapy, 18, 451-460.

comments powered by Disqus

Sponsors, Associates, and Links >>

Copyright © 2016 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.